Japan's biotech moment: A briefing for drug developers, investors and partners

Japan wants you: Accelerating global drug development and approval in a stable, proven market

Japan is actively opening its doors to foreign pharmaceutical and biotech companies. In recent years, the Japanese government has introduced a series of policies and regulatory reforms designed to make it easier for foreign companies to develop and get approval for their drugs in Japan.

In a landmark move, PMDA opened its first-ever U.S. office in Washington, D.C. in 2024, providing a direct channel for foreign companies seeking to navigate the Japanese regulatory landscape. Meanwhile, the National Cancer Center has launched the "ENSEMBLExJ Project", a dedicated consultation service that helps global sponsors conduct multi-regional clinical trials (MRCTs) in Japan.

Whether you are looking to expand your pipeline into a new market or accelerate your path to approval, Japan's latest initiatives offer tangible opportunities you won't want to miss.

sponsored by

Rare diseases, real urgency: Why Japan needs your drug now

Patients living with rare and intractable diseases in Japan are facing a critical challenge: too many overseas drugs remain inaccessible to them. This gap is not just a regulatory issue. For patients and their families, it is a matter of life.

Japan offers a compelling case for rare disease drug development. Incentives and support programs for rare disease sponsors are on par with those in the U.S. and Europe. Beyond that, Japan's universal health insurance system provides robust financial protection for all citizens, while patients with designated intractable diseases benefit from additional government support — ensuring that approved treatment can reach those who need them most.

If you are developing a rare disease therapy, Japan's patients are waiting. Let's work together to close the gap.

sponsored by

From capital to cure: How Japan's V-ECO program is accelerating biotech pipelines

Five years ago, Japan's Ministry of Economy, Trade and Industry (METI) launched the Venture Capital Ecosystem Enhancement Program — known as the V-ECO Program — with a bold goal: to accelerate private investment into pre-IPO biotech companies working on drug development.

Here's how it works. AMED, Japan's funding agency, certifies select venture capital firms. When a certified VC invests in an eligible pre-IPO biotech with a qualifying pipeline, that biotech receives a matching grant from AMED worth twice the VC's investment. The program is already gaining traction globally. Several international VC firms have received certification and are actively exploring opportunities to leverage V-ECO funding for their portfolio companies.

In this session, you will hear directly from the METI officials who run the V-ECO Program, alongside leaders from certified international VC firms. Whether you are a biotech founder or an investor looking to maximize your returns in Japan, this is a session you won't want to miss.

sponsored by

Expert panel

Stay tuned -- more to come.

sponsored by